Tag: The Conversation

WORLD DIABETES DAY: Nearly 80 South Africans Die from Diabetes Daily – UP Expert Calls for Urgent National Action

An illustration of blood glucose monitoring, an important aspect of diabetes management and the prevention of complications. Source: Pixabay CC0

PRETORIA – Diabetes has remained South Africa’s leading underlying natural cause of death for three consecutive years, claiming nearly 29 000 lives in 2024 alone. A University of Pretoria (UP) public health expert is calling for urgent action to strengthen healthcare and prevent avoidable deaths.

According to the latest Statistics South Africa mortality report, 28 767 South Africans died from diabetes-related complications in 2024. This represents 6.1% of all recorded deaths, or about 79 people every day.

Diabetes was also the leading underlying natural cause of death in 2022 and 2023, with 33 126 and 27 967 deaths, respectively.

Dr Patrick Ngassa Piotie, co-founder of UP’s Diabetes Research Centre and Chairperson of the Diabetes Alliance, says these figures expose a persistent public health crisis that demands immediate intervention.

“These numbers cannot be accepted as South Africa’s new normal,” he says. “Diabetes is mostly preventable and manageable. With timely support, people can lead long, healthy lives free from preventable complications.”

Diabetes is a chronic condition in which the body cannot properly regulate blood sugar levels. Without appropriate treatment, it can cause life-threatening complications affecting the heart, kidneys, eyes, and blood vessels.

Women and working-age adults are most at risk

The national statistics reveal significant inequalities in the burden of diabetes.

In 2024, diabetes claimed 17 429 women’s lives, accounting for 7.9% of all recorded female deaths. Among men, it caused 11 334 deaths, representing 4.5% of male deaths.

Working-age South Africans are also particularly vulnerable. Diabetes was the leading natural cause of death among people aged 45 to 64, accounting for 9 364 deaths, or 7.9% of deaths in this age group.

It also ranked as the leading natural cause of death in five provinces: Gauteng, KwaZulu-Natal, Western Cape, Eastern Cape, and Limpopo.

The findings reflect a broader national health challenge, with noncommunicable diseases, including diabetes and cardiovascular conditions, accounting for 60.7% of all recorded deaths in 2024.

Why better healthcare could save lives

Dr Ngassa Piotie argues that mortality statistics tell us how many lives have been lost to diabetes, but reveal little about the circumstances surrounding those deaths, including whether they could have been prevented through earlier diagnosis, timely treatment, and better-quality care.

“We should not wait until people die to identify where our health system is failing them,” he says. “We must use the evidence available today to improve care, prevent avoidable complications, and save lives.”

Death certificates cannot reveal whether patients received timely diagnoses, had reliable access to medication, or were regularly monitored for complications.

Through UP’s Tshwane Insulin Project, researchers have demonstrated how nurse-led care can help patients with type 2 diabetes start and adjust insulin treatment at primary healthcare facilities, supported by follow-up care at home.

“Survival rarely hinges on high-tech interventions,” Dr Ngassa Piotie says.

Instead, effective diabetes care depends on trained healthcare workers, reliable medicine supplies, regular screening, continuous monitoring, and support that accommodates patients’ everyday circumstances.

From policy to action: Preventing avoidable deaths

South Africa’s National Strategic Plan for Non-Communicable Diseases includes targets known as 90-60-50. These aim to ensure that 90% of adults know their blood pressure and blood glucose status, 60% of those with elevated levels receive treatment, and 50% of those receiving care achieve clinical control.

However, translating these commitments into effective healthcare remains a challenge.

Dr Ngassa Piotie advocates for the establishment of a national diabetes registry and the integration of digital health systems to track patients from diagnosis through treatment, identify those who discontinue care, and monitor complications.

He identifies three immediate priorities: connecting early diagnosis to sustained treatment, measuring healthcare outcomes across districts and provinces, and addressing socio-economic barriers such as food insecurity, transport costs, and limited healthcare access.

Following the 2025 Diabetes Summit, the Diabetes Alliance launched the Johannesburg Declaration for Accelerated Action on Diabetes in South Africa, calling for coordinated national leadership, sustainable financing, and stronger primary healthcare.

For Dr Ngassa Piotie, preventing avoidable diabetes-related deaths requires more than awareness campaigns. It demands a coordinated national response that ensures patients receive the continuous care they need.

“People living with diabetes must help define what quality care looks like,” he says.

Read Dr Ngassa Piotie’s full article in The Conversation.

Experimental Brain Implants are on the Rise. What Happens After the Trials are Over?

AI image created with Grok

Nathan Higgins, Monash University

In 2024, Elon Musk’s Neuralink put its first brain implant into a human amid doubt from scientists and allegations of animal cruelty.

Two and a half years later, that first patient is one of more than 20 “neuralnauts” who use their implants to participate in the online world.

Brain implants are becoming smaller, more compatible with human bodies, and dramatically more capable. People with paralysis can use brain-computer interfaces to produce speech almost instantaneously. Earlier this year, researchers in the United Kingdom showed volunteers wearing a headset could control robotic limbs and their natural ones at the same time.

As the industry takes off, we will see more and more clinical trials of devices that are implanted in the brain. In a recent study, my colleagues and I tried to address an increasingly important question: when a clinical trial of an experimental neural device ends, what does that mean for the human participants?

Tough questions

There is no simple answer. Some participants may be able to continue using an implanted device “off-label” as part of a special access scheme, or if the trial sponsor enrols participants into a follow-up study.

But if the trial sponsor is funded by a research grant or venture capital, they may not be able to cover the costs of potentially lifelong device support.

Participants may need to have their device removed at the end of the trial, even if they have benefited from it.

These scenarios are not hypothetical.

This is becoming a significant issue in Australia, where a new generation of neurotech companies is taking off.

Last year, Melbourne-based company EpiMinder received FDA authorisation to market their continuous seizure monitoring system for epilepsy.

Synchron has raised well over A$300 million for its “minimally invasive” endovascular brain-computer interface and has recently commenced its latest Australian clinical trial.

No rules, yet

Yet Australia currently has no rules about how trial organisers should be required to support participants for the long term.

Nor are there rules about how participants should be supported when trials are suspended or devices discontinued.

Current guidance offers little direction on what ethical arrangements should involve.

The Australian clinical trial handbook requires researchers to “clearly explain” whether participants will have continued access. However, this is difficult in practice.

Trials of implantable systems often last several years. This makes it difficult for participants to anticipate what their future needs and preferences will be once the trial comes to a conclusion.

Asking the experts

We brought together an expert panel of 24 clinicians, bioengineers, consultants, bioethicists and research governance professionals to develop recommendations on post-trial responsibilities in Australia.

If the sponsor is able to give participants the option of post-trial use, we recommend giving participants and their loved ones a realistic picture of what continued use will look like.

Which clinical and technical supports will remain available, and who will provide them? Will surgery and maintenance be covered by public healthcare or private health insurance? What costs might participants face themselves?

Years may pass before a device receives regulatory approval or becomes eligible for reimbursement. Participants should be provided with updates on changes to funding, regulatory status or manufacturers’ commercial plans that could affect their ongoing care.

This does not always happen in neurotechnology research. Transparency helps participants assess their participation and plan for life after the trial.

Geographic barriers

Geographic and socioeconomic factors also bear on continuing access to device support. Trials are often run from metropolitan teaching hospitals. Some participants may need to make repeated visits to the trial site for outpatient care or inpatient stays.

Flights and accommodation may need to be arranged for participants who must travel interstate, particularly as laws around psychosurgery vary between states. This can complicate access to local care.

We recommend anticipating barriers to continuing device use that may disproportionately affect some participants. During recruitment and study design, research teams should engage participants’ primary treating physicians to discuss what aspects of post-trial support can be safely (and lawfully) taken on locally.

Some procedures will still require specialist expertise, but sharing post-trial support could reduce travel costs and dependence on the original research team. Better treatment for pioneersThe end of a clinical trial should not mean losing access to a device when better planning and coordination between trial organisers could have made continued use possible.

Ultimately, these trial participants are pioneers who put their brains in researchers’ hands to help develop promising new treatments.

Nathan Higgins, Postdoctoral Research Fellow, Monash Bioethics Centre, Monash University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

79 Deaths a Day: South Africa’s Diabetes Crisis Needs a New Strategy

Photo by Wes Dissy on Unsplash

Patrick Ngassa Piotie, University of Pretoria

Statistics South Africa (Stats SA) recently released its report on deaths that occurred in 2024. The headline findings contain a sobering, recurring truth: diabetes was once again the country’s leading underlying natural cause of death.

In 2024 alone, 28 767 people died from complications caused by diabetes, accounting for 6.1% of all deaths nationwide. That is an average of nearly 79 deaths every day.

Diabetes also claimed the top spot in 2022 and 2023. These numbers cannot be accepted as South Africa’s new normal. Behind every data point is a human life, a grieving family and, all too often, years of encounters with a health system that missed opportunities to diagnose, treat and support people in time.

As a public health specialist and chairperson of the non-profit organisation Diabetes Alliance, I view this three-year trend as an unacceptable tragedy. Diabetes is manageable. With timely support, people can lead long, healthy lives free from preventable complications. Acknowledging this crisis is the start, but recognition must give way to political action. The Department of Health must establish a national diabetes strategy with clear targets for prevention and care. The finance minister must resource it. And the Presidency must lead a coordinated, whole-of-government response.

The broader health landscape is equally stark. Noncommunicable diseases accounted for 60.7% of all recorded deaths in 2024. The top three causes of natural death – diabetes, hypertensive diseases and cerebrovascular diseases – frequently overlap in the same individuals. Managing these interconnected conditions through isolated disease programmes makes little sense for primary care clinics or the patients navigating them.

Reading beyond the numbers

At first glance, the 2024 total is 800 deaths higher than the revised 2023 figure of 27,967 (5.8% of recorded deaths). Stats SA compiles these mortality figures from death notification forms filed through the Department of Home Affairs. Medical practitioners record the cause of death, which Stats SA then classifies using international coding standards. Late death registrations and administrative backlogs are processed retroactively; this leads to revision or updating of prior years’ totals.

The updated count for 2022 stood at 33,126, higher than diabetes deaths recorded in 2023 and 2024. Diabetes has remained South Africa’s single largest natural killer for three consecutive years.

The diabetes burden is also deeply unequal:

  • Women bear the heaviest loss: diabetes was the leading recorded natural cause among women, claiming 17,429 lives (7.9% of all female deaths) and 11,334 or 4.5% of all male deaths.
  • Working-age adults are hard hit: it ranked first among people aged 45-64, accounting for 9,364 deaths (7.9% of deaths in this group).
  • Geographic split: diabetes ranked as the top natural cause in five provinces, Western Cape, KwaZulu-Natal, Limpopo, Eastern Cape and Gauteng, while hypertensive diseases led in the remaining four provinces. These provincial rankings are not a measure of individual care quality or residency. They are a starting point for region-specific questions about access and system performance.

The geographic split shows the need to investigate whether access to diagnosis, treatment and good quality care differs between and within provinces.

A death certificate is only the final chapter

Mortality statistics record the primary cause listed on a death notification, but remain blind to what happened along the way.

They cannot tell us how many South Africans live with undiagnosed diabetes. They cannot show whether a patient had consistent access to insulin and testing supplies, whether their blood sugar was adequately controlled, or whether a simple follow-up could have prevented a fatal complication. Nor do they capture the full toll of diabetes when another condition is listed as the underlying cause.

Those are the questions we must answer while patients are still alive.

In my work on strengthening diabetes care, including the Tshwane Insulin Project – a nurse-led programme that helped people with type 2 diabetes start and adjust insulin treatment in primary care, with follow-up support at home – I have seen where care pathways break down, and where they succeed. Survival rarely hinges on high-tech interventions. It depends on the links in primary healthcare:

  • a trained clinic nurse with the time to act
  • a reliable supply chain for medicines and diagnostics
  • routine follow-up mechanisms when a patient misses an appointment
  • regular screening for kidney, eye and vascular (blood vessel) complications
  • support systems that respect the economic reality of a person’s daily life.

We need real-time clinical data that helps a facility respond today, not a national death tally published two years later.

Turning policy into frontline care

South Africa already has a framework: the National Strategic Plan for Non-Communicable Diseases and its 90-60-50 targets. This cascade aims to ensure that 90% of adults know their blood pressure and blood glucose status, 60% of those with elevated levels receive treatment, and 50% of those receiving care achieve clinical control.

The challenge is making policy work in practice.

Tools like the National Health Laboratory Service diabetes dashboard offer valuable insights into blood sugar levels control across districts. But to close the loop, South Africa urgently needs a national diabetes registry and integrated digital tracking to understand who enters care, who remains in care, and who is being left behind.

From declaration to delivery

After the 2025 Diabetes Summit, the Diabetes Alliance launched the Johannesburg Declaration for Accelerated Action on Diabetes. The declaration calls for coordinated national leadership, sustainable financing, decentralised primary care, and direct participation by people living with diabetes. It asks the Presidency to lead a multisectoral response and calls on the National Treasury and health sector to match policy commitments with financial resources.

The latest mortality report gives this agenda even more urgency. There are three practical priorities:

  1. Connect early diagnosis to sustained care. Screening is only useful if a positive result leads to uninterrupted treatment, reliable medicines, blood glucose monitoring and clinical review.
  2. Measure quality of care: publish a picture of diagnosis, treatment, retention and complication rates by district and province.
  3. Address the conditions in which health choices are made. Food prices, transport barriers and economic hardship shape health outcomes.

People living with diabetes must help define what quality care looks like. Their experience should guide national policy and daily clinic operations alike.

Patrick Ngassa Piotie, Chairperson, Diabetes Alliance; Co-founder, Diabetes Research Centre, University of Pretoria

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Pope Leo XIV’s Lung Cancer Highlights Growing Number of Nonsmokers Diagnosed with the Disease – And Younger People Too

By Edgar Beltrán, The Pillar – Own work, CC BY-SA 4.0, Link

Estelamari Rodriguez, University of Miami

When many people think of an average lung cancer patient, they often imagine an older man smoking. But the face of lung cancer has changed. Over the past 15 years, more women, never smokers and younger people are being diagnosed with lung cancer.

In fact, lung cancer is the leading cause of cancer death among women, and more women die from lung cancer than breast, ovarian and colorectal cancer each year. The American Lung Association reports that while lung cancer rates have risen by 79% for women over the last 44 years, they decreased by 43% for men. And for the first time in history, there are more young women than men diagnosed with lung cancer.

News about Pope Leo XIV’s lung cancer diagnosis on Oct. 13, 2026, sparked discussion about increasing rates of the disease among people who have never smoked. Leo reportedly is not a smoker. Potential causes for the disease include environmental exposures and genetics, and recognising the diverse factors that can increase someone’s risk of lung cancer – regardless of their smoking history – is essential for timely and appropriate screening and treatment.

Cancer that is found at the earliest stages, like that of the pope, can be treated with surgery and cured for both smokers and nonsmokers. The challenge is that people who have never smoked are not currently included in lung cancer screening guidelines, and tumours are often only found by chance.

As a thoracic oncologist, I have seen many younger women and never smokers walk into my clinic with a new diagnosis of lung cancer. Particularly for never smokers, lung cancer is unexpected for both patients and their doctors, which can often lead to delays in diagnosis. Researchers have described this trend of increasing lung cancer rates among women in different parts of the world and are starting to understand why cases are on the rise.

Lung cancer in women

The first explanation of why rates of lung cancer in women have increased is that many started smoking later than men, pushing back their peak in smoking-related lung cancer diagnoses.

Women also started smoking in the years when filtered cigarettes were most commonly used. This led to an increased risk of a type of cancer called adenocarcinoma due to the way cigarette filters distribute tobacco smoke to the outer parts of the lungs. Some studies suggest that women are more susceptible to the carcinogenic effects of exposure to tobacco and cigarette smoke, including second-hand smoke, and may develop lung cancer after fewer years of smoking compared to men.

However, it is important to note that most people diagnosed today with lung cancer are not active smokers. About 20% of women with lung cancer have never smoked – higher than for men with lung cancer who’ve never smoked. An increasing number of lung cancer diagnoses are among people who never smoked.

Lung cancer risk factors

Besides smoking and secondhand smoke, there are several other lung cancer risk factors. These include a family history of cancer and exposure to asbestos, radon and air pollution.

Exposure to carcinogens in the workplace in the form of inhaled chemicals such as arsenic, beryllium, cadmium, silica and nickel is still a concern in some parts of the world. The potential lung cancer risk of e-cigarette and marijuana smoke is still under study but of potential concern.

Recently, researchers have also found that genetics can play a role in lung cancer risk in some patients with a strong history of lung cancer. Studies of these families have helped identify potential susceptibility genes for lung cancer and environmental risk factors.

Like BRCA1 and BRCA2 in breast cancer, alterations in genes that promote or protect against tumour development can contribute to lung cancer development. Researchers have yet to identify specific mutations that may predispose individuals to lung cancer. However, studying familial genetic predispositions can help elucidate how lung cancer develops and lead to new biomarkers for early cancer detection in high-risk groups.

Lung cancer screening

In 2021, the United States Preventive Services Task Force updated its lung cancer screening guidelines to include younger patients with less smoking history. Now, lung cancer screening is recommended for adults ages 50 to 80 who have smoked at least one pack per day for 20 years, current smokers and former smokers who quit smoking within the last 15 years. Women at risk for lung cancer can talk to their doctors about ordering a low-dose CT scan for lung cancer screening.

Nationwide, more than 70% of eligible women undergo breast cancer screening but less than 6% of all eligible smokers pursue lung cancer screening. Researchers estimate that these new screening guidelines will increase the number of women eligible for lung cancer screening by 40% by including those at a younger age who have less smoking exposure.

A low-dose CT scan can help with early detection of lung cancer. In this image, the tumour is the white nodule in the upper right corner of the black space. Atlas of Pulmonary Pathology/Flickr, CC BY-SA

Lung cancer diagnosis

In recent years, increasing understanding of the genetic changes that can lead to cancer and how to harness the immune system to treat cancer has led to new targeted therapies and immunotherapies that have improved the prognosis of patients with lung cancer. Women tend to have a better lung cancer prognosis than men, especially if they never smoked and have tumours with molecular changes that can be treated with targeted therapies.

However, lung cancer symptoms may go unrecognised in women. Symptoms of lung cancer can include coughing, shortness of breath, overwhelming fatigue and pain in the back, chest or shoulder, which could be confused for other ailments. Because women tend to be slightly younger when diagnosed than men, patients may be able to tolerate symptoms longer and delay seeking medical attention. Physicians also might not attribute these symptoms to lung cancer due to a patient’s younger age.

Recognising the early symptoms of lung cancer, expanding lung cancer screening eligibility and testing for genetic biomarkers to select the best therapy are some of the steps that could help address the global epidemic of lung cancer in women.

This is an updated version of an article published on Feb. 1, 2023.

Estelamari Rodriguez, Associate Director of Community Outreach in Thoracic Oncology, University of Miami

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Parasitic Worms Could Hold the Key to Treating Immune System Diseases – Here’s What we Know

Dr. Roshan Nasimudeen, CC BY-SA 3.0 , via Wikimedia Commons

Eilis Dowd, University of Galway and Sienna Stucke, University of Galway

For millions of years, parasitic worms have had to survive inside animals without being destroyed by their hosts’ immune systems. To do that, they have evolved remarkably effective ways of dampening the immune response.

Scientists are now trying to understand those tricks and work out whether they could be turned into medicines for diseases resulting from overactive immune systems.

Parasitic worms, also known as helminths, include roundworms, tapeworms, hookworms and flukes. Many live and feed in the intestines of their hosts, including humans. They still infect up to 1.5 billion people worldwide each year.

Although they can be unpleasant, these parasites deserve some grudging respect. They have evolved ways to survive inside their hosts for years and even decades. For scientists interested in autoimmune, inflammatory and allergic conditions, that’s a remarkable skill.

The human immune system walks a constant tightrope – it must be aggressive enough to fight off viruses, bacteria and parasites, but controlled enough to avoid damaging the body’s own tissues. Sometimes that balance breaks down.

There are three main ways the immune system can turn against its host. In autoimmune diseases, the immune system mistakenly attacks the body’s own cells and tissues. In inflammatory conditions, an excessive or prolonged immune response can damage healthy tissue and cause chronic symptoms. In allergic diseases, the immune system overreacts to otherwise harmless substances, treating them as dangerous threats.

Over time, scientists noticed that rates of these immune conditions were much higher in countries that had largely rid themselves of parasite infections. This led to the old friends hypothesis, which suggested that our co-evolution with the parasites inside us may have benefited our immune systems.

Scientists then wondered whether deliberately infecting patients with live parasites or their eggs could be used as a therapy. By the early 2000s, the idea had moved from an intriguing hypothesis into human clinical trials. One early example involved Trichuris suis, the pig whipworm. Patients with inflammatory bowel diseases were given 2,500 whipworm eggs to swallow, and over time, their disease symptoms improved.

Patients were given pig whipworm to swallow. Pexels/Corinna Widmer

However, deliberately infecting patients with parasites is a difficult idea to get people to accept. For this reason, researchers began to take a closer look at our “old friends” and what tricks they evolved to deceive our immune systems. It turns out that they secrete a whole array of molecules that can convince the immune system to allow them to live and feed inside their hosts. These molecules act on the immune cells to tamp down their activity.

Now, instead of giving patients live parasites, there is the intriguing possibility of using their molecules as drugs to alter or regulate the immune system.

Hundreds of studies have now investigated worm-derived molecules from dozens of parasite species. In research published in Scientific Reports and Molecular Therapy, we gathered this evidence together and showed that parasitic molecules calm the immune system in animal models of asthma, arthritis, rhinitis, colitis, sepsis and diabetes.

Animals with asthma could breathe more easily, those with arthritis had less pain and more mobility, those with sepsis did not die of septic shock, and so on across all the disease models investigated.

In another piece of research, from the University of Galway in Ireland, scientists prevented multiple sclerosis in mice treated with a molecule from the liver fluke.

Multiple sclerosis shares something important with the other conditions mentioned above – it is an autoimmune disease in which the immune system mistakenly attacks nerve cells, impairing their function. But multiple sclerosis is also unique because it is the only brain disease in which molecules from parasites have been tested as potential treatments.

Could parasite molecules have beneficial effects for other brain conditions where inflammation plays a role? Inflammation is involved in many neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease, and coincidentally, incidences of these conditions have also risen since we largely banished parasites.

Are we there yet?

There is still a long road between an intriguing molecule and a medicine. A drug that works in a mouse or rat can fail in humans because our biology is more complex. But there are reasons for cautious optimism. Scientists can now isolate the molecules parasites produce, identify the processes they affect in the human body and modify them into potential drugs. AI could accelerate that search by helping scientists sift through vast numbers of molecules and predict which are most likely to work.

The hope is not that parasites themselves will become medicines, but that millions of years of evolution may have already solved some of the biological problems we are still trying to understand – and that new tools might help us borrow some of their answers.

Some of the most valuable medicines have come from unlikely places. It may be that one of nature’s least popular creatures has been carrying important lessons about controlling inflammation all along.

Eilis Dowd, Professor of Pharmacology and Therapeutics, University of Galway and Sienna Stucke, PhD Candidate in Pharmacology and Therapeutics, University of Galway

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Pollen Season: New Map of South Africa’s Allergy Hotspots Gives You Time to Prepare

Photo by Andrea Piacquadio on Pexels

Trevor Hill, University of KwaZulu-Natal; Andriantsilavo Hery Isandratana Razafimanantsoa, University of Cape Town; Caryn Upton, University of Cape Town; Dilys Berman, University of Cape Town; Frank Neumann, North-West University; Jemma Finch, University of KwaZulu-Natal; Jonny Peter, University of Cape Town, and Takudzwa Matuvhunye, University of Cape Town

For some South Africans, the beginning of the flower season is met not with the joys of spring but rather with a sniffy nose, itchy eyes and a cacophony of sneezing.

In South Africa, allergic rhinitis (hayfever) affects an estimated 20% to 30% of the population – children and adults. Asthma affects around 20% of children and 10% of adults. Air pollution can worsen asthma and eczema symptoms and cause eczema.

Most people recognise that pollen, despite being invisible to the naked eye, is a dominant airborne allergen driving conditions like hayfever. Sufferers are acutely aware that pollen in the air changes seasonally, depending on what is flowering.

But South Africans still know too little about when pollen seasons begin and end, or how they differ across the country. This is because there’s been very little consistent, long-term pollen monitoring. Without local records showing when different plants release pollen, it’s hard for doctors to identify what is causing a patient’s allergy. People with allergies are also left guessing when to start taking medicines that could prevent their symptoms.

Now, a pioneering scientific initiative is changing that. The South African Pollen Monitoring Network, set up seven years ago, sourced equipment and built research teams in different cities. The network has now produced South Africa’s first five-year pollen calendars for several different natural regions. These calendars show which plants release pollen in each region, when they release it and how pollen levels change during the year.

Previously, pollen was measured in only a few African cities, and researchers used different methods, making it difficult to compare the results. The new network uses the same method to collect pollen from the air at all its sites. However, many pollen grains look so similar that scientists can identify only the plant family, such as grasses, rather than the exact species.

The network covered inland grassland sites in Johannesburg and Bloemfontein, and savanna sites in Pretoria and Kimberley. Its coastal sites represented fynbos in Cape Town, the Indian Ocean coastal belt in Durban and Albany thicket in Gqeberha.

We are medical and environmental researchers who have studied pollen for more than 50 years collectively. Together with MSc candidate Yolanda Makgale, we formed a team that constructed these pollen calendars.

We found that grass was the most common pollen everywhere, Bloemfontein had the highest overall pollen levels, Johannesburg had the most tree pollen, and Kimberley the most grass pollen.

This research is important because these calendars could help doctors diagnose and manage allergies and support warnings about periods of high pollen exposure.

The pollen causing allergies in inland cities

Over five years, South African Pollen Monitoring Network researchers identified 103 types of pollen across seven South African cities. Grass produced the most pollen and was the main cause of pollen allergies. Inland cities had much higher pollen levels than coastal cities, and their grass pollen seasons lasted for more than 200 days a year.

Bloemfontein (grassland biome): highest total amount of pollen recorded over a year, mainly because of its high levels of grass and tree pollen. Grass released pollen for an average of 246 days each year – about eight months.

Kimberley (savanna biome): highest average concentration of grass pollen, with an open, grassy landscape and a grass season lasting, on average, 247 days a year.

Johannesburg (grassland biome): highest average tree pollen, probably due to its large “urban forest” of planted exotic trees.

Pretoria (savanna biome): high tree pollen counts, dominated by the exotic Morus (mulberry) tree, which contributed 25% to the total pollen catch.

Coastal cities

In contrast to the inland cities, coastal cities recorded lower overall pollen loads and shorter grass seasons, often under 100 days a year. This difference is likely due to coastal rainfall washing the pollen out of the atmosphere, combined with strong coastal winds.

Cape Town (fynbos biome): the longest tree pollen season in the country, lasting 297 days a year, starting early in July. The pollen profile is dominated by exotic trees, with Cupressaceae (cypress) accounting for 30% of the five-year average, followed by Myrtaceae (eucalyptus) at 11%, and Pinus (pine) at 9%.

Durban (Indian Ocean coastal belt): low overall pollen catch, with the shortest grass season in the study, lasting just 71 days and starting late in summer.

Gqeberha (Albany thicket biome): lowest overall annual pollen load among all seven cities, alongside the shortest tree (116 days) and grass (92 days) seasons.

Climate change impact on pollen allergies

Between 2019-2021 and 2022-2024, pollen levels fell across most regions. Grass pollen nearly halved, while tree pollen doubled in inland cities. Researchers now need to examine whether rainfall, weather, flowering seasons or changes in land use caused this shift.

Climate change may play a part by changing pollen levels and seasons. It can also increase the risk of “thunderstorm asthma”. During some storms, moisture bursts grass pollen into tiny pieces that winds push towards the ground. When inhaled, they can cause sudden and dangerous asthma attacks.

What this means for allergic patients

For people suffering from hay fever or asthma, calendars tailored to South Africa’s specific regions can act as an early warning system. Knowing exactly when pollen season starts lets patients begin preventive treatments, such as antihistamines or nasal sprays, before their symptoms start.

The new data revealed surprising allergy triggers. For instance, birch tree pollen, a major cause of hay fever in the northern hemisphere, was detected across South Africa where it is an ornamental, non-indigenous tree planted in gardens.

The general public may underestimate the dominant role of exotic trees in driving pollen load in big cities like Cape Town, Johannesburg and Pretoria. This finding should feed into decisions about what to plant.

What needs to happen next

Five years of pollen data show why year-round monitoring matters for public health. Researchers want to extend monitoring into rural areas and include pollen warnings in the national health system. They also hope to use DNA testing to identify allergy-causing plants that look identical under a microscope.

For now, the calendars help South Africans see which pollen is in the air, when levels are highest and when they may need to take precautions.

Funding came from Wellcome Trust (grant number: 311673), Cipla, Twinsaver, UCT Lung Institute Postdoctoral Research Fellow Award, a CSIR Parliamentary Grant, Novartis, University of Cape Town, Thermo Fisher Scientific, Clicks, Glenmark Pharmaceuticals, Dr Reddy’s, SA Natural Products, and Zeiss Africa.

Trevor Hill, Professor, Department of Geography, University of KwaZulu-Natal; Andriantsilavo Hery Isandratana Razafimanantsoa, Postdoctoral Research Fellow at the UCT Lung Institute, University of Cape Town; Caryn Upton, Medical Research Officer, Division of Allergology and Clinical Immunology, University of Cape Town; Dilys Berman, Lecturer and aerobiologist in the division of Allergology and Clinical Immunology, Department of Medicine and UCT Lung Institute, University of Cape Town; Frank Neumann, Professor of Geology, North-West University; Jemma Finch, Associate Professor of Geography and Palaeoecologist, University of KwaZulu-Natal; Jonny Peter, Associate Professor, Unit Head and also serves as Head of the Division of Allergology and Clinical Immunology at Groote Schuur Hospital, University of Cape Town, and Takudzwa Matuvhunye, Postdoctoral Researcher at the UCT Lung Institute, University of Cape Town

This article is republished from The Conversation under a Creative Commons license. Read the original article.

One in Eight Cancers are Likely Caused by an Infection Worldwide – New Study

Photo by CDC on Unsplash

John (Eddie) La Marca, WEHI (Walter and Eliza Hall Institute of Medical Research) and Sarah Diepstraten, WEHI (Walter and Eliza Hall Institute of Medical Research)

Around 12% of the world’s total cancer cases in 2024 were likely caused by an infection, according to new research from the World Health Organization (WHO).

The study, published today in The Lancet Oncology, analysed the frequency and causes of different cancers, specifically examining the role of infections.

It linked 2.3 million new cancer cases to an infection. Most were caused by just five pathogens: Helicobacter pylori (4%), human papillomavirus, or HPV (4%), hepatitis B (2%), Epstein-Barr virus (1%) and hepatitis C (under 1%). These infections can cause more than 20 different types of cancer, including stomach, liver, blood and cervical cancers.

So, how can an infection cause cancer? And does this mean these cancers are preventable?

Did we already know about this link?

Some of the study authors have been researching this field for around thirty years. Their previous work investigated cancer cases caused by infections in 1990, 2002, 2008, 2012, and 2018. The proportion of cancer cases caused by infections may appear to have dropped during those years (from a high of 18% in 2002), but the authors stress these comparisons cannot really be made confidently, as the sources and quality of the data have changed over time.

In fact, the latest study wasn’t trying to compare between the years. Instead, it aims to highlight where controlling and preventing infections can help to reduce cancer rates.To make sense of this, it helps to know how infection is linked to cancer. Extensive research has dissected the molecular mechanisms behind this link, and we now know there are various ways infections can cause cancer.

How can a virus cause cancer?

A virus can (directly or indirectly) change the genes of the cell it infects (the host cell), making that cell more likely to grow out of control and eventually become a cancer.There are three main ways viruses can do this.

The first is by turning off the ability of a cell to destroy itself (for example, by inactivating the TP53 protein) or to stop dividing (for example, by inactivating the RB protein). A healthy cell would normally try to do these things if infected by a virus. The second way a virus can cause cancer is by inserting its own DNA into the host cell’s DNA, which can accidentally disrupt genes that control cell death or division (like those above). The third way is when the virus itself carries a gene that causes cancer (an oncogene). In many cases, the virus has picked up these by accident from another organism. The link between viruses and cancer is actually foundational to modern cancer science, and has helped scientists uncover the direct link between genetics and cancer we now take for granted.

What about bacteria and parasites?

It’s not just viruses that cause cancer. Infections from bacteria or parasites – such as Helicobacter pylori (best known for causing stomach ulcers), or Opisthorchis viverrini (a liver fluke, a type of parasitic worm) – can also lead to cancer. However, these work more indirectly than viruses. Long-term (chronic) infection by these types of organisms can cause significant stress to different tissues. Inflammation, normally a part of the body’s immune response, can then become overactive, damaging the tissues further. These stresses can result in cancer-causing DNA damage in cells, or lead to mistakes during cell division as the body tries to rapidly produce new cells to repair tissue damage. In both cases, the cells acquire genetic mutations that put them on the road towards becoming cancer.

Many cancers are preventable

Of course, there may be other mechanisms linking infections and cancer that we don’t know about but, overall, the connection between infections and cancer is indisputable. Critically, what this tells us – and what this new study into the rates of cancers caused by infections reinforces – is that many cancers are preventable.

In Australia, one of the best examples of preventing cancers caused by infections is the human papillomavirus (HPV) vaccine. This vaccine protects against certain strains of HPV strongly associated with cervical cancer, and is available to adolescents in Australia. Since the program began in 2007, HPV infections dropped by 90% among people eligible to receive the vaccine. Because of its success, Australia could be on track to eliminate cervical cancer by 2035. However, vaccination rates among 15-year-olds have fallen from 85.7% in 2020 to 79.5% in 2024, which is concerning. As is the case for all vaccines, a high proportion of the population need to be vaccinated to also protect those who, for health reasons, cannot be vaccinated. For HPV, the WHO and Australian target is to vaccinate 90% of 15-year-old girls by 2030.

Sadly, the new study also highlights that around 75% of cancers caused by infections were found in low- and middle-income countries.Treating infections that can lead to cancer – such as HIV, H. pylori, and hepatitis B and C – is one way to reduce cancer rates. Preventative measures also play a major role, including vaccinations, condoms and disease screening. However, the availability of these programs in poorer countries can be limited, and so access continues to be a major equity issue in combating cancer.

The authors would like to acknowledge the contribution of Amali Cooray from the Olivia Newton-John Cancer Research Institute to this article.

John (Eddie) La Marca, Senior Research Officer, Blood Cells and Blood Cancer, WEHI (Walter and Eliza Hall Institute of Medical Research) and Sarah Diepstraten, Senior Research Officer, Blood Cells and Blood Cancer Division, WEHI (Walter and Eliza Hall Institute of Medical Research) This article is republished from The Conversation under a Creative Commons license. Read the original article.

The Bias in Medical Research: Africa Carries a Huge Disease Burden but Is Missing from Clinical Trials

Bamba Gaye, MD, MPH, MSc, PhD, Emory University

Modern medicine prides itself on being a universal science, built on evidence from clinical trials.

But there’s a bias in medical research. While Africa accounts for roughly 25% of the global disease burden and 19% of the global population, the continent’s people are largely invisible in some clinical trials.

The scale of the erasure is revealed in a landmark study of 2,472 randomised controlled trials globally published between 2019 and 2024.

I led this team of researchers, who scrutinised the world’s most influential medical publications to quantify African representation. They included the New England Journal of Medicine, The Lancet, the Journal of the American Medical Association, Nature Medicine, and the British Medical Journal. There were also three leading cardiovascular journals in the study: Circulation, the European Heart Journal and the Journal of the American College of Cardiology.

I am a physician-scientist working at the intersection of cardiometabolic epidemiology and biomedical data science. I also focus on large-scale population studies in Africa and data-driven cardiovascular prevention.

Randomised controlled trials are a cornerstone of evidence-based medicine. Introduced in the mid-20th century, they rigorously evaluate the safety and effectiveness of treatments by randomly assigning participants to different groups. This is done to minimise bias. Trials like these have been central to major medical breakthroughs, from cardiovascular therapies to vaccines. They continue to guide clinical decisions and the development of new treatments worldwide.

What we discovered

Our findings show a profound imbalance in the global clinical research landscape. Across the five most prestigious general medical journals, only 3.9% of trials were conducted exclusively in Africa. In cardiovascular health, the numbers drop to a statistical whisper. Of the major trials published in leading cardiology journals, just two studies (0.6%) were conducted solely on African soil.

This is a crisis of scientific accuracy. When clinical trials exclude African populations, they produce evidence that lacks “external validity”. This refers to how well the results of a study can be generalised beyond the participants. It asks whether findings from a clinical trial will still hold true when applied to different populations, settings, or real-world conditions.

Without that validity, doctors are essentially conducting unmonitored experiments on millions of patients every day.

Modern medicine cannot claim to be universal if entire populations remain invisible in the evidence base. Biology, health systems and disease patterns are not identical across the world.

The gap and why it matters

Many treatments used across the continent are based on evidence generated in non-African populations, raising concerns about their applicability.

Moreover, most Africa-based trials still focus on infectious diseases, despite the rising burden of non-communicable diseases such as cardiovascular disease.

Emerging evidence shows that genetics, environment and diet can radically alter how a body responds to a drug. It therefore makes no medical sense that an entire continent is left out of the trial net.

There’s also evidence showing that certain treatments have different safety profiles in Black patients. Diabetes and gout are just two examples. So are certain common blood pressure medications, such as angiotensin-converting enzyme (ACE) inhibitors. Research shows that they carry a three- to four-fold higher risk of severe, life-threatening side effects in people of African descent compared to other populations.

When clinical trials exclude populations, doctors are forced to extrapolate findings from one population and apply them to another.

The study also highlights a dangerous lag between global research funding and the evolving reality of African health. The new data show that nearly 76% of trials conducted exclusively in Africa focused on infectious diseases. But the continent is undergoing a massive epidemiological shift. Non-communicable diseases – heart disease, stroke, and diabetes – now account for about 38% of all deaths in many African nations.

The middle class in Africa has tripled to 300 million people from roughly 100 million people in the early 2000s. More people are now living long enough with lifestyles that increase the risk of chronic conditions such as heart disease, diabetes, and hypertension. Consequently, there is a growing need and market for long-term treatments that manage these diseases, rather than short-term therapies for infections. Yet cardiovascular trials continue to be discouraged.

Even within the continent, the data show deep “black holes” of information. South Africa accounted for over 62% of all trials conducted on the continent. Central Africa, a region that’s home to more than 180 million people, was virtually non-existent in the global research record. It contributed less than 3% of the continent’s limited trial output. Possible reasons include South Africa’s decades of cumulative investment, seen in stronger academic hubs, research governance, experienced trial units, and more established sponsor relationships. Other regions face barriers like fewer resourced research institutions, less access to trial platforms, and sometimes language and publication issues that can reduce visibility in top-tier journals.

The inequity extends into the hierarchy of science itself. Even when African sites are included in large, multicontinental trials, they are often relegated to the role of “recruitment hubs” rather than scientific partners. Our study found that African scientists led only 3.6% of multicontinental trials that included an African site.

Towards a new era of African science

Africa should not simply be a location where studies are conducted.

It must be a place where research is conceived, led and interpreted. The current model creates a cycle of external dependence where international institutions manage the funding and the data. This leaves local research systems fragile and unable to translate evidence into national policy.

There is need for “ring-fenced” funding for African-led research, the development of regional trial networks, and a mandate for medical journals to report on the diversity of trial populations.

There are signs of a rising momentum. Organisations like Alliance for Medical Research in Africa are working to equip a new generation of African investigators. Africa must create a research ecosystem that is too important for the global community to ignore.

Bamba Gaye, MD, MPH, MSc, PhD, Adjunct professor, Emory University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Melatonin May Help Ease Chronic Muscle and Joint Pain, New Study Suggests

Made with AI

Dipa Kamdar, Kingston University

Melatonin is best known for helping us sleep. But a new study suggests it might have another surprising use: easing muscle and joint pain.

Produced naturally by the pineal gland in the brain at night, melatonin helps regulate the body’s sleep-wake cycle. That’s why this hormone is widely used as a treatment for insomnia and jet lag.

Sleep and pain are closely linked (poor sleep can make pain feel worse, and pain can make sleep harder). But melatonin may also reduce pain directly. Researchers believe it dampens pain signals in the brain and spinal cord, reduces inflammation, calms overactive nerves and protects cells from oxidative stress – the cellular wear and tear caused when harmful molecules build up.

In the new study, researchers combined the results of 23 clinical trials involving over 2,000 participants to identify overall patterns. These trials looked at melatonin for long-term muscle and joint pain as well as pain after surgery.

Overall, melatonin reduced both pain and sleep problems in people with chronic muscle and joint pain. But the improvements were modest. On average, pain scores fell by about nine points on a 100-point scale. That’s within the range reported for some anti-inflammatory drugs in similar studies, although the two treatments haven’t been directly compared.

Melatonin’s effects may also depend on whether people already have sleep problems or other long-term health conditions. Most of the chronic pain studies included people who already had poor sleep to begin with, but none of the trials looked at results separately for people with and without sleep issues. Because of this, it’s unclear whether melatonin works better for people who struggle with sleep or whether the effects are similar for everyone.

The findings were much less convincing for pain after surgery. Melatonin did not make a noticeable difference to pain or sleep. One analysis found a tiny improvement (about 2.5 points on a 100-point pain scale), but this is far below what would matter to patients recovering from surgery.

The benefits in chronic muscle and joint pain are modest. Based on the current evidence, melatonin should be seen as a possible add-on treatment rather than a replacement for established therapies. The evidence suggests melatonin could complement treatments such as physiotherapy, exercise and anti-inflammatory medicines rather than replace them.

What we still don’t know

There is also still a lot we don’t know. The trials in this study used a wide range of doses, from 1mg to 10mg, and the researchers couldn’t determine which dose worked best.

There were hints that longer treatment helped more in chronic pain, but this was based on only a few studies. There is also very little evidence on the effectiveness of higher doses, even though they appear safe in other studies.

Melatonin is widely used and generally considered safe for short-term use, but it can cause side-effects, such as daytime sleepiness, dizziness, headaches and nausea.

People with liver or kidney conditions, or those with autoimmune conditions like rheumatoid arthritis, should speak with a doctor or pharmacist before taking it.

It is also worth noting that melatonin is regulated very differently around the world. In the US, melatonin is sold as a dietary supplement, meaning people can buy it easily in supermarkets and online without medical advice. But in the UK, melatonin is a prescription-only medicine and is only licensed for short-term sleep problems and jet lag.

For now, the findings suggest melatonin may offer modest relief for some people with chronic muscle and joint pain, particularly if poor sleep is part of the problem. It’s unlikely to replace established treatments, but it could eventually earn a place alongside them. Larger, well-designed trials will be needed before doctors can say with confidence who is most likely to benefit.

Dipa Kamdar, Senior Lecturer in Pharmacy Practice, Kingston University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Women Report Poor Sleep Despite a Good Night’s Rest – While Men Overestimate Their Own Sleep Quality

Men reported sleeping better than they objectively did, while the opposite was true for women. Photo by Ketut Subiyanto on Pexels

Torbjörn Åkerstedt, Karolinska Institutet

Disturbed sleep is a common problem — and one that has many serious consequences beyond feeling tired the next day. Research has linked insomnia and poor sleep to early mortality and diseases including diabetes and cardiovascular disease.

Women often report experiencing disturbed sleep more frequently than men. They also constitute the majority of patients in sleep clinics. Yet strangely, some studies show worse objective sleep quality in men – a bit of a paradox.

To understand what might explain the paradox, my colleagues and I conducted a study that directly compared sleep quality ratings and objective sleep measures between men and women.

We found that women complained more of sleep problems – but slept objectively much better than men. We think this paradox can probably be explained by men overestimating their sleep quality as they’re less able to perceive how often they wake up at night.

A total of 238 randomly selected women participated in the study, plus 238 men who were matched on age and BMI with the women to ensure similar participants were compared against each other.

Sleep was recorded in each participant’s home using a recorder that measured brain waves (electroencephalography – EEG), muscle tension (electromyography – EMG) and eye movements (electrooculography – EOG). These devices tracked what stage of sleep a participant was in and for how long, how much time they spent awake and how quickly they fell asleep.

A researcher visited the participant’s home in the evening, mounted the recording equipment and left. The participant went to bed and awoke at their usual time.

In the morning, the participant rated the degree of difficulty they had falling asleep, if their sleep was restless, if they woke up early, how often they thought they’d woken up, how long it took them to fall asleep, how long they slept and their overall sleep quality.

The sleep recording was scored by a sleep technician based on visual inspection of the EEG, EOG and EMG recordings. The data was then analysed to understand the objective quality of each participant’s sleep and its relation to gender and age.

Analyses were also adjusted for factors such as gender, age and alcohol consumption and smoking, which may affect sleep.

Sleep quality

The results show that women subjectively reported significantly lower sleep quality than men. Yet women actually had considerably fewer nighttime awakenings, less stage one (superficial) sleep and higher sleep efficiency (they spent more time asleep while in bed). Women also experienced more stage three (deep) sleep and slept longer (400 minutes versus 382 minutes for men).

When women did wake up at night, they spent more time awake on average. Photo by Cottonbro on Pexels

The results suggest that women objectively had a good nights’ sleep, compared to men. The only variable that suggests worse sleep in women was that when they did wake up at night, they spent more time awake than men did – around nine minutes each time for women versus just under seven minutes for men.

It only takes around five minutes of being awake at night for a person to remember it the next morning. This may explain why women were better able to remember if they’d woken up the night before and estimate how many times they had. Men, on the other hand, grossly underestimated their number of awakenings (by 72% compared to women’s 37%).

For other quantitative measures, like time to fall asleep, sleep duration and time awake, men and women were equally good at estimating their objective values. And they were relatively correct.

We took this further and found that men who only woke up for a short period of time during the night (around eight minutes or so each time they woke up) often didn’t remember they had.

When this group of men was removed, no gender difference in subjective sleep quality remained. This suggests that men with short nighttime awakenings report better sleep quality than would be expected from their objective sleep measures as they didn’t remember they’d woken up.

It’s also noteworthy that men’s objective sleep deteriorated faster with age than women. This was particularly obvious for stage three sleep. While women aged over 65 got around 80 minutes of stage three sleep each night, men had only 53 minutes. Among those between 30 and 50 years of age, the amount was similar for men and women (around 70 minutes).

Sleep and wellbeing

A key reason women may complain of having a worse nights’ sleep than they objectively had may therefore be the amount of time they spent awake when they woke up, making it easier for them to notice. Likewise, men may overestimate their sleep quality because they’ve spent less time awake when they’ve woken up, so they don’t remember it happening.

Both findings would work towards reducing subjective sleep quality in women and increasing it in men. We assume then, that the experience of awakenings has an important influence on subjective sleep quality.

As our study was only conducted over one night, it will be important for future research to investigate whether these findings remain when participants are studied over longer periods of time.

Future studies may also want to explore the reasons for poor sleep in men – especially since common sources of disturbed sleep, such as alcohol, smoking and BMI, were all adjusted for in our analysis. Researchers may also want to investigate why men’s sleep becomes objectively worse as they get older.

Our research illustrates how sleep quality doesn’t just involve the physiological aspects of sleep. It also includes our own subjective experiences, which can impact our wellbeing and how rested we feel.

It also suggests that because many men overestimate their sleep quality, they may also overlook any sleep problems they’re experiencing. This could mean that some men aren’t getting help for conditions that could be affecting their health and wellbeing.

Torbjörn Åkerstedt, Senior Professor of Psychology, Department of Clinical Neuroscience, Karolinska Institutet

This article is republished from The Conversation under a Creative Commons license. Read the original article.